SEEL Stock - Seelos Therapeutics, Inc.
Unlock GoAI Insights for SEEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $2.20M | N/A | N/A | N/A | $375,000 |
| Gross Profit | $-27,914,000 | $-53,000 | N/A | N/A | $-22,188,000 |
| Gross Margin | -1267.1% | N/A | N/A | N/A | -5916.8% |
| Operating Income | $-40,499,000 | $-70,916,000 | $-61,669,000 | $-18,759,000 | $-29,747,000 |
| Net Income | $-37,882,000 | $-76,138,000 | $-67,533,000 | $-19,220,000 | $-50,383,000 |
| Net Margin | -1719.6% | N/A | N/A | N/A | -13435.5% |
| EPS | $-7.73 | $-21.48 | $-22.29 | $-12.88 | $-74.43 |
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.
Visit WebsiteEarnings History & Surprises
SEELEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 12, 2025 | — | — | — | — |
Q2 2025 | May 12, 2025 | — | — | — | — |
Q1 2025 | Mar 4, 2025 | — | — | — | — |
Q4 2024 | Nov 19, 2024 | — | — | — | — |
Q3 2024 | Aug 14, 2024 | $-152.49 | $1.92 | +101.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-1.48 | $-25.60 | -1629.7% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.80 | $-0.79 | +1.3% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.06 | $-1076.28 | -1793700.0% | ✗ MISS |
Q3 2023 | Sep 29, 2023 | $-0.09 | $-0.22 | -144.4% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.11 | $-461.26 | -419227.3% | ✗ MISS |
Q1 2023 | Mar 10, 2023 | $-0.13 | $-0.17 | -30.8% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.10 | $-691.89 | -691790.0% | ✗ MISS |
Q3 2022 | Aug 5, 2022 | $-1153.15 | $-768.77 | +33.3% | ✓ BEAT |
Q2 2022 | May 10, 2022 | $-1076.28 | $-499.70 | +53.6% | ✓ BEAT |
Q1 2022 | Mar 4, 2022 | $-3.30 | $-1076.28 | -32514.5% | ✗ MISS |
Q4 2021 | Nov 5, 2021 | $-345.95 | $-422.82 | -22.2% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-653.45 | $-307.51 | +52.9% | ✓ BEAT |
Q2 2021 | Apr 30, 2021 | $-0.09 | $-1076.28 | -1195766.7% | ✗ MISS |
Q1 2021 | Mar 11, 2021 | $-0.08 | $-0.13 | -62.5% | ✗ MISS |
Q4 2020 | Nov 12, 2020 | $-0.08 | $-345.95 | -432337.5% | ✗ MISS |
Latest News
Frequently Asked Questions about SEEL
What is SEEL's current stock price?
What is the analyst price target for SEEL?
What sector is Seelos Therapeutics, Inc. in?
What is SEEL's market cap?
Does SEEL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SEEL for comparison